In April 2026, Processa Pharmaceuticals announced that Dr. Sian Bigora, Chief Development and Regulatory Officer, will transition from full-time executive duties to a part-time role effective May 1, 2026 [S3]. This leadership change occurs alongside active clinical programs focused on NGC-Cap for breast cancer and PCS12852 for gastroparesis, with the latter’s licensing agreement recently lapsed without renewal [S15]. The company faces ongoing challenges including FDA regulatory uncertainties linked to staffing and funding constraints [S2], Nasdaq listing pressures resolved through a reverse stock split in late 2025 [S25], and capital demands highlighted by a net loss of approximately $13.56 million in fiscal 2025 against limited revenue and modest cash reserves [F1]. Upcoming clinical data readouts and potential licensing developments will be pivotal for Processa’s growth trajectory.